Sign in Subscribe

phase-ii

A collection of 44 issues

Encorafenib, cetuximab, and nivolumab rechallenge succeeds in BRAF V600E mCRC case

Skip to content The CRC Digest Encorafenib, cetuximab, and nivolumab rechallenge succeeds in BRAF V600E mCRC case A case report from the AGMT mCRC Registry describes successful rechallenge with encorafenib and cetuximab combined with nivolumab in a patient with BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer. (Clinical Colorectal Cancer) This

AZUR-4 Phase II trial tests neoadjuvant dostarlimab plus CAPEOX in MSS stage III colon cancer

Skip to content The CRC Digest ◆ TRIAL DATA AZUR-4 Phase II trial tests neoadjuvant dostarlimab plus CAPEOX in MSS stage III colon cancer This randomized Phase II study compares neoadjuvant dostarlimab plus CAPEOX versus CAPEOX alone in previously untreated T4N0 or stage III mismatch repair proficient/microsatellite stable resectable colon

ctDNA-guided rechallenge with cetuximab plus irinotecan shows activity in RAS/BRAF wild-type mCRC

Skip to content The CRC Digest ▸ TREATMENT ctDNA-guided rechallenge with cetuximab plus irinotecan shows activity in RAS/BRAF wild-type mCRC A Phase II trial enrolled patients with RAS/BRAF wild-type metastatic colorectal cancer who had progressed on prior cetuximab-based therapy, using circulating tumor DNA testing to select patients for rechallenge

Dual Oral Regimen Shows Activity in KRAS G12C–Mutated Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Dual Oral Regimen Shows Activity in KRAS G12C–Mutated Metastatic CRC A phase Ib/II trial evaluated the chemotherapy-free combination of ifebemtinib (a FAK inhibitor) plus garsorasib (a KRAS G12C inhibitor) in previously treated KRAS G12C–mutated metastatic colorectal cancer, showing encouraging antitumor

Direct inhibitors for KRAS G12D and G12V mutations now in development for colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH Direct inhibitors for KRAS G12D and G12V mutations now in development for colorectal cancer While approved KRAS therapies target only the rare G12C mutation, new drugs including MRTX1133, zoldonrasib, and daraxonrasib are being developed to directly target G12D and G12V—the most common

Combination Therapy Shows Activity in KRAS G12C-Mutated Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Combination Therapy Shows Activity in KRAS G12C-Mutated Metastatic CRC A phase 1b/2 trial found that ifebemtinib plus garsorasib demonstrated anticancer activity and manageable safety in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer, though the improvement in response rate did not

Immunotherapy Combination Achieves Complete Response and Polyp Regression in dMMR Colorectal Cancer

Skip to content The CRC Digest Immunotherapy Combination Achieves Complete Response and Polyp Regression in dMMR Colorectal Cancer Case report from the NOUS-209-01 trial describes a patient with mismatch repair-deficient colorectal cancer who achieved complete pathologic response and significant colonic polyp regression following treatment with Nous-209 plus pembrolizumab. (Journal of

Combination therapy targets KRAS G12C mutation in metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Combination therapy targets KRAS G12C mutation in metastatic CRC The Lancet Oncology published results showing encouraging antitumor activity of ifebemtinib combined with garsorasib in previously treated patients whose metastatic colorectal cancer harbors the KRAS G12C mutation. (The Manila Times) This content is informational

Ifebemtinib plus garsorasib shows antitumor activity in KRAS G12C metastatic colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Ifebemtinib plus garsorasib shows antitumor activity in KRAS G12C metastatic colorectal cancer A combination of ifebemtinib and garsorasib demonstrated encouraging antitumor activity in previously treated metastatic colorectal cancer patients with KRAS G12C mutations, according to results published in The Lancet Oncology. (The Manila

Final Analysis of DEEPER Trial Shows No Survival Difference Between Cetuximab and Bevacizumab in RAS/BRAF Wild-Type mCRC

Skip to content The CRC Digest ◆ TRIAL DATA Final Analysis of DEEPER Trial Shows No Survival Difference Between Cetuximab and Bevacizumab in RAS/BRAF Wild-Type mCRC The phase II DEEPER trial found no differences in progression-free survival or overall survival in the per-protocol set when comparing modified-FOLFOXIRI plus cetuximab versus